{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T08:08:31Z","timestamp":1793347711204,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jdsjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jdermsci.2026.07.004","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T23:05:35Z","timestamp":1783983935000},"page":"133-140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Longitudinal BRAF ctDNA monitoring in melanoma reflects disease status and predicts relapse"],"prefix":"10.1016","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1821-8836","authenticated-orcid":false,"given":"Daniel","family":"Rizo-Potau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7053-8044","authenticated-orcid":false,"given":"Anton","family":"Forni\u00e9s-Marin\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3856-2060","authenticated-orcid":false,"given":"Edgard","family":"Verdura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1842-9441","authenticated-orcid":false,"given":"Aina","family":"Montalb\u00e1n-Casafont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1231-4651","authenticated-orcid":false,"given":"Laura","family":"Serra-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4150-0522","authenticated-orcid":false,"given":"Sebastian","family":"Podlipnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1608-8820","authenticated-orcid":false,"given":"Cristina","family":"Carrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1337-9745","authenticated-orcid":false,"given":"Susana","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6998-914X","authenticated-orcid":false,"given":"Josep","family":"Malvehy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4345-9631","authenticated-orcid":false,"given":"Joan Anton","family":"Puig-Butill\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdermsci.2026.07.004_bib1","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024","volume":"215","author":"Garbe","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jdermsci.2026.07.004_bib2","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1177\/12034754231188434","article-title":"Surveillance After a Previous Cutaneous Melanoma Diagnosis: A Scoping Review of Melanoma Follow-Up Guidelines","volume":"27","author":"Johnston","year":"2023","journal-title":"J. Cutan. Med. Surg."},{"key":"10.1016\/j.jdermsci.2026.07.004_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.suronc.2024.102077","article-title":"Surveillance evaluations in patients with stage I, II, III, or resectable IV melanoma who were treated with curative intent: A systematic review","volume":"54","author":"Rajagopal","year":"2024","journal-title":"Surg. Oncol."},{"key":"10.1016\/j.jdermsci.2026.07.004_bib4","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.bjps.2023.07.026","article-title":"NICE 2022 guidelines on the management of melanoma: Update and implications","volume":"85","author":"Lakshmi","year":"2023","journal-title":"J. Plast. Reconstr. Aesthetic Surg. JPRAS"},{"key":"10.1016\/j.jdermsci.2026.07.004_bib5","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024","volume":"215","author":"Garbe","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jdermsci.2026.07.004_bib6","first-page":"472","article-title":"Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jdermsci.2026.07.004_bib7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2024.11.006","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Amaral","year":"2025","journal-title":"Ann. Oncol. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.jdermsci.2026.07.004_bib8","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.3390\/cancers16142572","article-title":"Clinical and Imaging Follow-Up for High-Risk Cutaneous Melanoma: Current Evidence and Guidelines","volume":"16","author":"Vetto","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.jdermsci.2026.07.004_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.772165","article-title":"Predictive Performance of Serum S100B Versus LDH in Melanoma Patients: A Systematic Review and Meta-Analysis","volume":"11","author":"Janka","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jdermsci.2026.07.004_bib10","article-title":"Reconsidering S100B: Why it is time to abandon its use in detecting disease recurrence in stage III melanoma patients","volume":"50","author":"Jansen","year":"2024","journal-title":"Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol."},{"key":"10.1016\/j.jdermsci.2026.07.004_bib11","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1056\/NEJMoa2404139","article-title":"Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma","volume":"391","author":"Long","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jdermsci.2026.07.004_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114327","article-title":"Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 \/ KEYNOTE-054 trial","volume":"211","author":"Eggermont","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jdermsci.2026.07.004_bib13","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1038\/s41591-023-02583-2","article-title":"Adjuvant nivolumab in resected stage IIB\/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial","volume":"29","author":"Kirkwood","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.jdermsci.2026.07.004_bib14","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1200\/JCO.23.02355","article-title":"Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study","volume":"42","author":"Luke","year":"2024","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.jdermsci.2026.07.004_bib15","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jdermsci.2026.07.004_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102788","article-title":"Circulating tumor DNA-based assessment of molecular residual disease in non-metastatic melanoma","volume":"129","author":"De Simoni","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jdermsci.2026.07.004_bib17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejca.2021.09.019","article-title":"Circulating tumour DNA (ctDNA) in metastatic melanoma, a systematic review and meta-analysis","volume":"158","author":"Gracie","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jdermsci.2026.07.004_bib18","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/cncr.34716","article-title":"Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients","volume":"129","author":"Eroglu","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.jdermsci.2026.07.004_bib19","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6660571","article-title":"Prognostic Value of ctDNA Mutation in Melanoma: A Meta-Analysis","volume":"2021","author":"Zheng","year":"2021","journal-title":"J. Oncol."},{"key":"10.1016\/j.jdermsci.2026.07.004_bib20","doi-asserted-by":"crossref","first-page":"8604","DOI":"10.1021\/ac202028g","article-title":"High-throughput droplet digital PCR system for absolute quantitation of DNA copy number","volume":"83","author":"Hindson","year":"2011","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jdermsci.2026.07.004_bib21","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S1470-2045(25)00139-1","volume":"26","author":"Syeda","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jdermsci.2026.07.004_bib22","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(20)30726-9","article-title":"Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study","volume":"22","author":"Syeda","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jdermsci.2026.07.004_bib23","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjd.18147","article-title":"Detection of cell-free circulating BRAFV600E by droplet digital polymerase chain reaction in patients with and without melanoma under dermatological surveillance","volume":"182","author":"Calbet-Llopart","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jdermsci.2026.07.004_bib24","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/annonc\/mdx717","article-title":"Circulating tumor DNA predicts survival in patients with resected high-risk stage II\/III melanoma","volume":"29","author":"Lee","year":"2018","journal-title":"Ann. Oncol. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.jdermsci.2026.07.004_bib25","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/annonc\/mdz048","article-title":"Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA","volume":"30","author":"Tan","year":"2019","journal-title":"Ann. Oncol. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.jdermsci.2026.07.004_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103978","article-title":"Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patients","volume":"9","author":"Genta","year":"2024","journal-title":"ESMO Open."},{"key":"10.1016\/j.jdermsci.2026.07.004_bib27","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1158\/1078-0432.CCR-25-3643","article-title":"Longitudinal ctDNA monitoring for post-surgical disease surveillance in patients with stage I-IIIB melanoma","volume":"32","author":"Ansstas","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jdermsci.2026.07.004_bib28","doi-asserted-by":"crossref","first-page":"5292","DOI":"10.1245\/s10434-025-17194-z","article-title":"Circulating Tumor DNA in High-Risk Stage II\/III Cutaneous Melanoma: A Feasibility Study","volume":"32","author":"Rhodin","year":"2025","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.jdermsci.2026.07.004_bib29","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1186\/s12967-024-05783-7","article-title":"Monitoring circulating tumor DNA liquid biopsy in stage III BRAF-mutant melanoma patients undergoing adjuvant treatment","volume":"22","author":"Marchisio","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.jdermsci.2026.07.004_bib30","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann. Oncol. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.jdermsci.2026.07.004_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105636","article-title":"Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA Workshop","volume":"114","author":"de Jager","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jdermsci.2026.07.004_bib32","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3343\/alm.2023.0389","article-title":"Clinical Practice Guideline for Blood-based Circulating Tumor DNA Assays","volume":"44","author":"Lee","year":"2024","journal-title":"Ann. Lab. Med."},{"key":"10.1016\/j.jdermsci.2026.07.004_bib33","doi-asserted-by":"crossref","first-page":"960","DOI":"10.3390\/cancers12040960","article-title":"Clinical Relevance of Liquid Biopsy in Melanoma and Merkel Cell Carcinoma","volume":"12","author":"Boyer","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.jdermsci.2026.07.004_bib34","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/pcmr.12623","article-title":"Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma","volume":"31","author":"Gangadhar","year":"2018","journal-title":"Pigment. Cell. Melanoma Res."},{"key":"10.1016\/j.jdermsci.2026.07.004_bib35","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1158\/1078-0432.CCR-19-3926","article-title":"Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors","volume":"26","author":"Lee","year":"2020","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.jdermsci.2026.07.004_bib36","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/clinchem\/hvaa125","article-title":"The Digital MIQE guidelines update: minimum information for publication of quantitative digital PCR experiments for 2020","volume":"66","author":"Huggett","year":"2020","journal-title":"Clin. Chem."},{"key":"10.1016\/j.jdermsci.2026.07.004_bib37","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/clinchem\/hvaa164","article-title":"Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based ctDNA Assays: A Joint Consensus Recommendation of the BloodPAC\u2019s Analytical Variables Working Group","volume":"66","author":"Godsey","year":"2020","journal-title":"Clin. Chem."},{"key":"10.1016\/j.jdermsci.2026.07.004_bib38","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jmoldx.2023.09.004","article-title":"Recommendations for Cell-Free DNA Assay Validations: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists","volume":"25","author":"Lockwood","year":"2023","journal-title":"J. Mol. Diagn. JMD"},{"key":"10.1016\/j.jdermsci.2026.07.004_bib39","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41586-019-1272-6","article-title":"Genome-wide cell-free DNA fragmentation in patients with cancer","volume":"570","author":"Cristiano","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jdermsci.2026.07.004_bib40","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.89083.3","article-title":"Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization","volume":"12","author":"Nguyen","year":"2023","journal-title":"eLife"},{"key":"10.1016\/j.jdermsci.2026.07.004_bib41","doi-asserted-by":"crossref","first-page":"6042","DOI":"10.1038\/s41467-023-41774-w","article-title":"Multimodal analysis of cell-free DNA whole-methylome sequencing for cancer detection and localization","volume":"14","author":"Bie","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jdermsci.2026.07.004_bib42","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41467-024-55428-y","article-title":"Multimodal cell-free DNA whole-genome TAPS is sensitive and reveals specific cancer signals","volume":"16","author":"Vavoulis","year":"2025","journal-title":"Nat. Commun."}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181126001210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181126001210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:00:26Z","timestamp":1788793226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181126001210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0923181126001210"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2026.07.004","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal BRAF ctDNA monitoring in melanoma reflects disease status and predicts relapse","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2026.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Japanese Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}